

RICHARD WHITLEY, MS Director

SUZANNE BIERMAN, JD, MPH Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES DIVISION OF HEALTH CARE FINANCING AND POLICY

1100 East William Street, Suite 101 Carson City, Nevada 89701 Telephone (775) 684-3676 • Fax (775) 687-3893 http://dhcfp.nv.gov

June 5, 2019

Inter-Tribal Council of Nevada Len George, ITCN President Tribal Chairman of Fallon Paiute Shoshone Tribe 565 Rio Vista Drive Fallon, NV 89406

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

Revisions to Medicaid Services Manual (MSM) Chapter 1200, Appendix A, are being proposed to reflect recommendations approved on April 25, 2019 by the Drug Use Review (DUR) Board. The proposed changes include revisions to the existing policy on Agents Used for the Treatment of Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Transdermal Fentanyl, Buprenorphine/Naloxone and Vivitrol® (naltrexone). These proposed changes also include the addition of new prior authorization criteria for LucemyraTM (lofexidine) and XyostedTM (testosterone enanthate).

There is no anticipated fiscal impact to the Tribal Government.

If you would like a consultation regarding this proposed change in policy, please contact Crystal Biselli at (775) 684-3722 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,

Tammy Moffitt

Chief of Operations

June 5, 2019 Page 2

Cc: Cody Phinney, Deputy Administrator, DHCFP
DuAne Young, Deputy Administrator, DHCFP
Holly Long, Social Service Program Specialist III (SSPS III), Pharmacy Services, DHCFP
Jodi Patton, Chief, Medical Programs, DHCFP
Briza Virgen, SSPS III, Medical Programs, DHCFP